186 related articles for article (PubMed ID: 9889125)
1. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes.
Durant ST; Morris MM; Illand M; McKay HJ; McCormick C; Hirst GL; Borts RH; Brown R
Curr Biol; 1999 Jan; 9(1):51-4. PubMed ID: 9889125
[TBL] [Abstract][Full Text] [Related]
2. The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast.
McA'Nulty MM; Lippard SJ
Mutat Res; 1996 Jan; 362(1):75-86. PubMed ID: 8538651
[TBL] [Abstract][Full Text] [Related]
3. Mlh2 is an accessory factor for DNA mismatch repair in Saccharomyces cerevisiae.
Campbell CS; Hombauer H; Srivatsan A; Bowen N; Gries K; Desai A; Putnam CD; Kolodner RD
PLoS Genet; 2014 May; 10(5):e1004327. PubMed ID: 24811092
[TBL] [Abstract][Full Text] [Related]
4. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
5. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
6. Multiple recombination pathways for sister chromatid exchange in Saccharomyces cerevisiae: role of RAD1 and the RAD52 epistasis group genes.
Dong Z; Fasullo M
Nucleic Acids Res; 2003 May; 31(10):2576-85. PubMed ID: 12736307
[TBL] [Abstract][Full Text] [Related]
7. Activation of Saccharomyces cerevisiae Mlh1-Pms1 Endonuclease in a Reconstituted Mismatch Repair System.
Smith CE; Bowen N; Graham WJ; Goellner EM; Srivatsan A; Kolodner RD
J Biol Chem; 2015 Aug; 290(35):21580-90. PubMed ID: 26170454
[TBL] [Abstract][Full Text] [Related]
8. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
9. Msh2 separation of function mutations confer defects in the initiation steps of mismatch repair.
Kijas AW; Studamire B; Alani E
J Mol Biol; 2003 Aug; 331(1):123-38. PubMed ID: 12875840
[TBL] [Abstract][Full Text] [Related]
10. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
11. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
12. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
13. Inverted repeat-stimulated sister-chromatid exchange events are RAD1-independent but reduced in a msh2 mutant.
Nag DK; Fasullo M; Dong Z; Tronnes A
Nucleic Acids Res; 2005; 33(16):5243-9. PubMed ID: 16166656
[TBL] [Abstract][Full Text] [Related]
14. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.
Lin X; Howell SB
Mol Cancer Ther; 2006 May; 5(5):1239-47. PubMed ID: 16731756
[TBL] [Abstract][Full Text] [Related]
15. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
16. Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants.
Abe H; Wada M; Kohno K; Kuwano M
Anticancer Res; 1994; 14(5A):1807-10. PubMed ID: 7531413
[TBL] [Abstract][Full Text] [Related]
17. DNA mismatch repair and mutation avoidance pathways.
Marti TM; Kunz C; Fleck O
J Cell Physiol; 2002 Apr; 191(1):28-41. PubMed ID: 11920679
[TBL] [Abstract][Full Text] [Related]
18. Saccharomyces cerevisiae MSH2-MSH3 and MSH2-MSH6 complexes display distinct requirements for DNA binding domain I in mismatch recognition.
Lee SD; Surtees JA; Alani E
J Mol Biol; 2007 Feb; 366(1):53-66. PubMed ID: 17157869
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitive and mitotic recombination phenotypes of the Saccharomyces cerevisiae dun1 mutant defective in DNA damage-inducible gene expression.
Fasullo M; Koudelik J; AhChing P; Giallanza P; Cera C
Genetics; 1999 Jul; 152(3):909-19. PubMed ID: 10388811
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair and treatment resistance in ovarian cancer.
Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
